Economic Outcomes Associated with Microvascular Complications of Type 2 Diabetes Mellitus
- 1 June 2009
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 27 (6) , 479-490
- https://doi.org/10.2165/00019053-200927060-00004
Abstract
Background: Patients with diabetes mellitus have been shown to be at high risk for both macrovascular and microvascular complications (MVC). Recent studies have focused on MVC and their effect on the healthcare system, but limited published data exist on long-term costs associated with MVC in patients with type 2 diabetes mellitus (T2DM). Objective: The objective of this study was to compare resource utilization and medical costs over a 12-month period among patients diagnosed with T2DM with versus without MVC in a managed-care population. Methods: Patients aged ≥18 years, diagnosed with T2DM between 1 January 2003 and 31 December 2004 were identified in an administrative claims database of approximately 55 million beneficiaries in private and public health plans. The date of the first T2DM diagnosis during this period was the ‘index date’ for each patient. All patients had to have a minimum of 12 months of continuous enrolment both prior to and following the index date. MVC was identified during the 12 months prior to the first T2DM diagnosis and these patients were matched (1:2) by age, sex and ten co-morbid conditions to those with no evidence of MVC during the entire study period. Results: Among the 15 326 MVC patients included in the study, 61% had a history of peripheral neuropathy, 28% diabetic retinopathy and 19% nephropathy. Compared with 30 652 patients without MVC, the MVC patients were more likely to use oral antidiabetics and insulin and had a higher co-morbidity score. Over 12 months, patients with MVC had more (mean 0.3 vs 0.2; p < 0.001) and longer (mean length of stay 1.79 days vs 0.85 days; p < 0.001) hospital stays; physician office visits (19.7 vs 13.7; p < 0.001); and prescriptions for oral antidiabetic (6.3 vs 5.6 scripts; p < 0.001) and insulin (0.7 vs 0.2 scripts; p < 0.001) use. Average total costs per patient over 12 months were $US14 414 with MVC versus $US8669 without MVC (p < 0.001). Conclusion: This study indicates that in patients with T2DM, MVC is associated with significant consumption of healthcare resources. Mean total costs with MVC were almost double those of patients without MVC over a 12-month period.Keywords
This publication has 16 references indexed in Scilit:
- Economic Burden and Risk of Cardiovascular Disease and Diabetes in Patients with Different Cardiometabolic Risk ProfilesValue in Health, 2007
- Diabetic microvascular complications: can patients at risk be identified? A reviewInternational Journal Of Clinical Practice, 2006
- Total and Component Health Care Costs in a Non-Medicare HMO Population of Patients With and Without Type 2 Diabetes and With and Without Macrovascular DiseaseJournal of Managed Care Pharmacy, 2006
- Treating diabetes to accepted standards of care: A 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United StatesClinical Therapeutics, 2005
- The Impact of Cardiovascular Disease on Medical Care Costs in Subjects With and Without Type 2 DiabetesDiabetes Care, 2002
- The prevalence of multiple diabetes‐related complicationsDiabetic Medicine, 2000
- Direct Medical Costs of Complications Resulting From Type 2 Diabetes in Hie U.S.Diabetes Care, 1998
- Impact of cardiovascular disease on health care utilization in a defined diabetic populationJournal of Clinical Epidemiology, 1994
- Presentation adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectivesJournal of Clinical Epidemiology, 1993
- The Wisconsin Epidemiologic Study of Diabetic RetinopathyArchives of Ophthalmology (1950), 1984